Medtronic's ablation system beats drug therapy in persistent AF trial, but fails on safety
This article was originally published in Clinica
Executive Summary
Medtronic's Phased radiofrequency (RF) ablation system has shown benefits over drug therapy in patients with persistent atrial fibrillation (AF), a group that is not currently treated with the technique and could represent a new market for cardiac ablation.